

Special Issue

Therapeutic Strategies for Diabetic Kidney Disease

Message from the Guest Editors

Diabetic kidney disease (DKD) is a worldwide public health concern. It is the leading cause of the end-stage renal disease (ESRD) and is strongly associated with a high cardiovascular death rate in patients with diabetes. The pathological significance of activated renin-angiotensin system (RAS) and hemodynamic changes is becoming increasingly evident, and a large number of diabetic patients are treated with RAS and/or SGLT2 inhibitors. While currently approved, these agents can retard but not completely prevent the progression to ESRD and cardiovascular events. Given the importance of DKD as a major risk factor for macrovascular complications, it is important to understand how this disease progresses and how the vascular disease is involved. In this Special Issue of *Diabetology*, we invite researchers to submit original research articles as well as review articles focusing on the molecular mechanisms of DKD. Contributions demonstrating original therapeutic opportunities or strategies for reducing cardiovascular complications are also encouraged.

Guest Editors

Dr. Keiichiro Matoba

Division of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishishinbashi, Minato-ku, Tokyo 105-8461, Japan

Dr. Naga Samji

Hospitalist in Tennova Health Center, Cleveland, TN, USA

Deadline for manuscript submissions

closed (25 May 2022)



Diabetology

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 2.5



mdpi.com/si/47062

Diabetology
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diabetology@mdpi.com

[mdpi.com/journal/
diabetology](https://mdpi.com/journal/diabetology)





Diabetology

an Open Access Journal
by MDPI

Impact Factor 2.4
CiteScore 2.5



[mdpi.com/journal/
diabetology](https://mdpi.com/journal/diabetology)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Peter Clifton

Division of Health Sciences, School of Pharmacy and Medical Sciences,
University of South Australia, Adelaide, SA 5000, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus, EBSCO, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 26 days after submission; acceptance to publication is undertaken in 4.8 days (median values for papers published in this journal in the first half of 2024).